VJOncology is committed to improving our service to you

BTOG 2020 | Chemoimmunotherapy, the UK & extensive-stage SCLC

VJOncology is committed to improving our service to you

Tom Newsom-Davis

Tom Newsom-Davis, BSc, MBBS, PhD, FRCP, Chelsea and Westminster Hospital NHS Foundation Trust, London, UK, discusses chemoimmunotherapy for extensive-stage small cell lung cancer (SCLC) commenting on whether UK clinical practice will change or persist with regards to this form of therapy. Dr Newsom-Davis specifically draws from the IMpower133 trial (NCT02763579), which investigated carboplatin plus etoposide with or without atezolizumab. This interview took place at the 18th British Thoracic Oncology Group (BTOG) 2020 congress held in Dublin, UK.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter